ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2523

Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

Megan E. B. Clowse1, Douglas C. Wolf2, Amanda Golembesky3, Laura Shaughnessy4, Dirk De Cuyper5 and Frauke Förger6, 1Rheumatology & Immunology, Duke University, Durham, NC, 2Atlanta Gastroenterology Associates, Atlanta, GA, 3UCB Pharma, Raleigh, NC, 48010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, 5Safety Patient Solutions BioBrands, UCB Pharma, Brussels, Belgium, 6Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: certolizumab pegol, pregnancy and rheumatic disease

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Data on the impact of anti-TNF medications on pregnancy outcomes are
limited. Certolizumab pegol (CZP) is a PEGylated
Fc-free anti-TNF approved in more than 50 countries for the treatment of
rheumatoid arthritis (RA) and/or Crohn’s disease, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The objective of
this project is to provide information on pregnancy outcomes in women receiving
CZP.

Methods: The
UCB Pharma safety database was searched for CZP-exposed pregnancies through 1
February 2015. Maternal and paternal CZP exposure, prospective and
retrospective reports were included. This abstract focuses on maternal exposure
pregnancies that are prospectively reported to reduce bias in outcome reporting
rates. Available data on CZP exposure, pregnancy dating, pregnancy outcomes,
comorbidities and infant events were independently extracted by 2 internal
reviewers. The number of live births, miscarriages, induced abortions and
stillbirths for CZP-exposed pregnancies were examined.

Results: There
were a total of 723 CZP exposed pregnancy reports, of which 572 were prospectively
reported. 540 pregnancies were maternally exposed (256 with known pregnancy
outcomes, 47.4%) and 32 were paternally exposed (18 with known outcomes,
56.3%). Of the 256 maternally exposed pregnancies with known outcome, there
were 207 live births (80.9%), 26 miscarriages (10.2%), 22 induced abortions
(8.6%), and 1 stillbirth (0.4%) (Figure). The majority of pregnancies were reported
through routine surveillance (65.9%); clinical trials accounted for 9.1% of
pregnancy reports. Indications for CZP use included rheumatic disease (n=100,
39.1%) and Crohn’s disease (n=140, 54.7%). The mean maternal age at estimated
delivery date was 31.3 (SD 5.4) years. Many pregnancies (n=70, 44.6%) were
exposed only during the first trimester, when the majority of fetal organ and
organ system development takes place; 52 were exposed to CZP in all 3
trimesters (Table). 9 cases of congenital malformations were prospectively
reported among 210 infants (including 3 sets of twins) with no discernable
pattern in the reported malformations.

Conclusion: The
analysis represents a uniquely large number of pregnancies exposed to a single
anti-TNF. The majority of pregnancies had first trimester CZP exposure, and up
to a third of prospectively-collected pregnancies continued treatment into the
second and/or third trimesters. A limitation of this study is that the majority
of the data originated from spontaneous post-marketing reports, which can be
affected by bias and inherent limitations due to the passive and voluntary
nature of the reporting systems. The data collectively suggests that CZP
exposure in utero does not adversely affect pregnancy outcome.


Disclosure: M. E. B. Clowse, UCB Pharma, 5; D. C. Wolf, Abbott, Bristol-Myers Squibb, Genentech, GIVEN Imaging, Janssen Biotech Inc., Millennium Research Group, Prometheus Laboratories, UCB Pharma, 2,Abbott, Genetech, GIVEN Imaging, Janssen Biotech Inc., Millennium Research Group, Prometheus Laboratories, Salix Pharmaceuticals, UCB Pharma, 5,Abbott, Janssen Biotech Inc., Prometheus, Salix, UCB Pharma, Warner Chilcott, 5; A. Golembesky, UCB Pharma, 3; L. Shaughnessy, UCB Pharma, 3; D. De Cuyper, UCB Pharma, 3; F. Förger, UCB Pharma, Roche, 5,UCB Pharma, Roche, 8.

To cite this abstract in AMA style:

Clowse MEB, Wolf DC, Golembesky A, Shaughnessy L, De Cuyper D, Förger F. Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/characteristics-and-outcomes-of-prospectively-reported-pregnancies-exposed-to-certolizumab-pegol-from-a-safety-database/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-and-outcomes-of-prospectively-reported-pregnancies-exposed-to-certolizumab-pegol-from-a-safety-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.